Protection from digoxin-induced coronary vasoconstriction in patients with coronary artery disease by calcium antagonists

American Journal of Cardiology

Volumn 83, Issue 3, 1999, Pages 440-442

  Nolte, Carsten W T ^a   Jost, Stefan ^a   Mügge, Andreas ^b   Daniel, Werner G ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLDIGOXIN; CALCIUM ANTAGONIST; DIGOXIN; GLYCERYL TRINITRATE; NISOLDIPINE;

ADULT; AGED; ARTERY DIAMETER; ARTICLE; CALCIUM ANTAGONISM; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; SYSTOLIC BLOOD PRESSURE;

ACETYLDIGOXINS; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY VASOSPASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NISOLDIPINE; NITROGLYCERIN; TREATMENT OUTCOME; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 0033081011     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00881-9     Document Type: Article

References (17)

1. Grupp I., Im W.B., Lee C.O. Relation of sodium pump inhibition to positive inotropy at low concentrations of ouabain in rat heart muscle. Am J Physiol. 36:1985;149-160.
2. Mason D.T. Afterload reduction and cardiac performance. Am J Med. 65:1979;106-125.
3. DeSanctis R.W., Block P., Hutter A.M. Tachyarrhythmias in myocardial infarction. Circulation. 45:1972;681-702.
4. James T. Myocardial infarction and atrial arrhythmias. Circulation. 24:1961;761-775.
5. Fleckenstein A., Fleckenstein-Grün G. Zur kombinierten Anwendung von Herzglykosiden und Calciumantagonisten. Arzneimittel-Forschg. 27:1971;736-742.
6. Mikkelsen E., Andersson K.-E., Lederballe Pedersen O. Effects of digoxin on isolated human peripheral arteries and veins. Acta Pharmacol Toxicol. 45:1979;249-256.
7. Schwartz J.S., Bache R.J. Effect of ouabain on large coronary artery diameter. J Cardiovasc Pharmacol. 11:1988;608-613.
8. Vatner S.F., Higgins C.B., Franklin D., Braunwald E. Effects of digitalis glycosides on coronary and systemic dynamics in conscious dogs. Circ Res. 28:1971;470-479.
9. DeMots H., Rahimtoola S.H., McAnulty J.H., Porter G.A. Effects of ouabain on coronary and systemic vascular resistance and myocardial oxygen consumption in patients without heart failure. Am J Cardiol. 41:1978;88-96.
10. Indolfi C., Piscione F., Russolillo E., Villari B. Digoxin-induced vasoconstriction of normal and atherosclerotic epicardial coronary arteries. Am J Cardiol. 68:1991;1274-1278.
11. Balcon R., Hoy J., Sowton E. Haemodynamic effects of rapid digitalisation following acute myocardial infarction. Br Heart J. 30:1968;373-376.
12. Varomkov Y., Shell W.E., Smirnov V., Jukovsky D., Chazov I. Augmentation of serum CPK activity by digitalis in patients with acute myocardial infarction. Circulation. 55:1977;719-720.
13. Dhein S., Müller A., Hegner M., Klaus W., Rosen R. Attenuation of ouabain-induced ST-segment depression and coronary spasm by nifedipine (abstr). Circulation. 74:(suppl):1988;II38.
14. Hausleiter J., Nolte C.W.T., Jost S., Wiese B., Sturm M., Lichtlen P.R. Comparison of different quantitative coronary analysis systems ARTREK, CAAS, and CMS . Cathet Cardiovasc Diagn. 37:1996;14-22.
15. Reiber J.H.C., Serruys P.W., Kooijmann C.J., Wijns W., Slager C.J., Gerbrands J.J., Schuurbiers J.C.H., Van den Boer B., Hugenholtz P.G. Assessment of short-, medium- and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation. 71:1985;280-288.
16. Hintze T.H., Vatner S.F. Reactive dilation of large coronary arteries in conscious dogs. Circ Res. 54:1984;50-57.
17. Godfraind T., Egleme C., Finet M., Jaumin P. The actions of nifedipine and nisoldipine on the contractile activity of human coronary arteries and human cardiac tissue in vitro. Pharmacol Toxicol. 61:1987;79-84.